Department of Medicinal Chemistry, College of Pharmacy, University of Florida, P.O. Box 100485, Gainesville, FL 32610, USA.
Curr Pharm Des. 2010;16(33):3638-45. doi: 10.2174/138161210794079227.
Current treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug entities have entered the market in the past years, many new potential pharmacophores are evolving. Among them, several drugs are in the pipeline that target cholecystokinin or corticotropin-releasing factor receptors, serve as inhibitors for specific tryptophan hydroxylase iso-enzymes, modulate chloride secretion, influence immune responses via monoclonal antibodies or ATP-mediated pathways, and even normalize the gastrointestinal microflora via supplementation with probiotics. While new treatments that act via chloride secretion and immune modulation present with favorable outcomes in clinical trials, other novel therapies require further evaluation. This review is intended to provide a synopsis of current and emerging pharmacotherapies for IBS.
目前针对慢性胃肠道疾病肠易激综合征（IBS）的治疗选择长期以来一直限于对症治疗，因为对该综合征的病理生理机制缺乏了解。然而，在过去的 10 年中，已经确定了许多新的药理学靶点，这些靶点可能有助于治疗肠易激综合征。尽管在过去几年中只有少数新的药物实体进入市场，但许多新的潜在药效基团正在发展中。其中，有几种药物正在研发中，这些药物的靶点是胆囊收缩素或促肾上腺皮质激素释放因子受体，作为特定色氨酸羟化酶同工酶的抑制剂，调节氯离子分泌，通过单克隆抗体或 ATP 介导的途径影响免疫反应，甚至通过补充益生菌来使胃肠道微生物群正常化。虽然通过氯离子分泌和免疫调节作用的新治疗方法在临床试验中表现出良好的结果，但其他新的治疗方法需要进一步评估。这篇综述旨在提供肠易激综合征当前和新兴的药物治疗方法概述。
